NCT07226869Recruiting
Computer Guided Microwave Liver Ablation
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the target tumor has, and has not been treated at any point during the procedure. The main questions it aims to answer are: 1) Does the use of the computer guidance software reduce the number of times a tumor is incompletely treated. 2) Does the use of the computer guidance software reduce the rate of local tumor recurrence at 2 year follow-up? 3) Was there an increase or a decrease in medical problems for participants after a procedure where the guidance software was used? Researchers will compare liver tumor treatment using the computer guidance software with an historic control to see if the addition of the guidance software improved the outcomes after an ablation. Participants will: Undergo CT-guided microwave ablation treatment of a liver tumor using computer-assisted simulation. Visit the clinic at one month and then every 3 months for blood tests and a contrast-enhanced CT or MRI imaging study (as per standard of care)
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 7 Nov 2025
- Start date
- 8 May 2026
- Primary completion date
- 28 Feb 2030
- Lead sponsor
- NE Scientific INC
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07226869
What you commit to
- Study type: Interventional
- Planned participants: 84
- From 8 May 2026 to the primary completion date, 28 Feb 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior local therapy to the target lesion (ablation, TACE, SBRT, or resection) or to a lesion within 1 cm of the target lesion
Other illness
- Contraindication to contrast-enhanced imaging (e.g., severe CKD without dialysis, contrast allergy not correctable with premedication)
- Active systemic infection
Other
- More than 5 hepatic lesions, or any lesion ineligible for technically complete ablation
- uncontrolled hepatic decompensation, including:
- o Persistent encephalopathy
- Uncorrectable coagulopathy or contraindication to percutaneous liver intervention
- Pregnancy
- Inability to comply with follow-up imaging schedule
Who the study is looking for
- Age ≥ 18 years, with life expectancy of at least 1 year
- Diagnosis of hepatocellular carcinoma (HCC) confirmed by:
- LI-RADS 5 imaging features or
- Histopathology
- Cirrhosis with AFP \> 400
- Localized disease without macrovascular invasion or extrahepatic metastasis, eligible for curative-intent percutaneous thermal ablation, defined as:
- o Up to 5 lesions with at least one lesion, 2 -5 cm, and no lesion \>5 cm diameter
- Tumor location deemed technically feasible for percutaneous ablation by the treating interventional radiologist
- ECOG Performance Status 0-2
- Adequate coagulation status, defined as:
- Platelets ≥ 50,000/μL
- INR ≤ 1.8 (or correctable)
- Ability to undergo contrast-enhanced CT or MRI
- Willingness and ability to provide informed consent
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Dartmouth Hitchcock Medical Center Coordinator of this site? Confirm its status | Lebanon | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.